Gene · 7006
Papers1,477
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 1,477
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial. | Ann Rheum Dis | 2023 | 37217273 | PubTator, text mining | PubMed |
| New small molecules in dermatology: for the autoimmunity, inflammation and beyond. | Inflamm Res | 2023 | 37212867 | PubTator, text mining | PubMed |
| Protein kinases: drug targets for immunological disorders. | Nat Rev Immunol | 2023 | 37188939 | PubTator, text mining | PubMed |
| How We Manage Patients with Indolent B-Cell Malignancies on Bruton's Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists. | Curr Oncol | 2023 | 37185435 | PubTator, text mining | PubMed |
| Stimulation of the catalytic activity of the tyrosine kinase Btk by the adaptor protein Grb2. | Elife | 2023 | 37159508 | PubTator, text mining | PubMed |
| CircRNAs: versatile players and new targets in organ fibrosis. | Cell Commun Signal | 2023 | 37131173 | PubTator, text mining | PubMed |
| Immune-Related Genes' Prognostic, Therapeutic and Diagnostic Value in Ovarian Cancer Immune-Related Gene Biomarker in Ovarian Cancer. | Cancer Control | 2023 | 37078136 | PubTator, text mining | PubMed |
| Myeloid Src-family kinases are critical for neutrophil-mediated autoinflammation in gout and motheaten models. | J Exp Med | 2023 | 37074415 | PubTator, text mining | PubMed |
| Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. | Lancet | 2023 | 37062298 | PubTator, text mining | PubMed |
| Enhancement of immune surveillance in breast cancer by targeting hypoxic tumor endothelium: Can it be an immunological switch point? | Front Oncol | 2023 | 37056346 | PubTator, text mining | PubMed |
| Bruton tyrosine kinase inhibitors for multiple sclerosis. | Nat Rev Neurol | 2023 | 37055617 | PubTator, text mining | PubMed |
| Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions. | Front Oncol | 2023 | 37035197 | PubTator, text mining | PubMed |
| Effects of prenatal pesticide exposure on the fetal brain and placenta transcriptomes in a rodent model. | Toxicology | 2023 | 37019170 | PubTator, text mining | PubMed |
| PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy. | Mol Cancer | 2023 | 36991452 | PubTator, text mining | PubMed |
| Structural Complementarity of Bruton's Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases. | Pharmaceuticals (Basel) | 2023 | 36986499 | PubTator, text mining | PubMed |
| Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety. | Cancers (Basel) | 2023 | 36980705 | PubTator, text mining | PubMed |
| Domain Architecture of the Nonreceptor Tyrosine Kinase Ack1. | Cells | 2023 | 36980241 | PubTator, text mining | PubMed |
| Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review. | Biomedicines | 2023 | 36979724 | PubTator, text mining | PubMed |
| Design, synthesis and evaluation of a series of potential prodrugs of a Bruton's tyrosine kinase (BTK) inhibitor. | Front Pharmacol | 2023 | 36969836 | PubTator, text mining | PubMed |
| Controlling Ibrutinib's Conformations about Its Heterobiaryl Axis to Increase BTK Selectivity. | ACS Med Chem Lett | 2023 | 36923918 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7006/papers?page=9